300016 Beijing Beilu Pharmaceutical
- 4.94
- -0.12-2.37%
Beijing Beilu Pharmaceutical News
Hokuriku Pharmaceutical (300016.SZ): The company's products do not involve biosynthesis technology
Gelonghui May 10 丨 Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company's products did not involve biosynthesis technology.
Hokuriku Pharmaceutical (300016.SZ): Jiuwei Zhenxin granules are the first pure traditional Chinese medicine preparation approved in China to treat generalized anxiety disorder
Gelonghui, April 22丨Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that Jiuwei Zhenxin granules are the first pure Chinese medicine formulation approved in China to treat generalized anxiety disorder. In order to improve patients' medication experience and improve patient compliance, the company is developing new prescriptions containing flavoring agents. The new flavor Jiuwei Zhenxin granules will be marketed and sold after approval by the corresponding drug regulatory authorities to better meet the medication needs of patients.
Hokuriku Pharmaceutical (300016.SZ) announced its 2023 annual results, changing profit to loss to 71.7571 million yuan
Hokuriku Pharmaceutical (300016.SZ) released its 2023 annual report. The company's revenue was 891 million yuan...
Hokuriku Pharmaceutical (300016.SZ): Currently, no relevant personnel training plans have been signed with universities
Gelonghui, April 12 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that at present, the company has not signed relevant talent training plans with colleges, but we attach great importance to cooperation and exchanges with universities to cultivate and introduce outstanding talents through school-enterprise internship base cooperation, etc. The company has established school-enterprise internship base partnerships with Hebei Medical University since 2019 and Shenyang Pharmaceutical University since 2020.
Hokuriku Pharmaceutical (300016.SZ): Actively expand the Internet and e-commerce channels of Jiuwei Zhenxin Granules
Gelonghui, April 9 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company is actively expanding the Internet and e-commerce channels of Jiuwei Zhenxin Granules. Up to now, the company's e-commerce division has actively cooperated with JD Health B2C Self-operated Jingdong Health Pharmacy, Ali Health B2C Self-operated Ali Health Pharmacy, Meituan B2C Self-operated Meituan Self-operated Pharmacy, and collaborated with JD Mutual Medical to research RWD real events and carry out platform strategic cooperation with Good Mood Internet Hospital.
Hokuriku Pharmaceutical (300016.SZ): Gadobelglutamine injection passed the consistency evaluation
Gelonghui, March 19, 丨 Hokuriku Pharmaceutical (300016.SZ) announced that recently, the company received the “Drug Supplement Application Approval Notice” (Notice No.: 2024B01144) issued by the State Drug Administration for gadolidine injections, and the gadolidine injection passed the consistent evaluation of the quality and efficacy of generic drugs. Gadobelglutamine injection is a paramagnetic contrast agent for diagnostic magnetic resonance imaging (MRI) of the liver, central nervous system, and blood vessels. According to data from the Mi Intranet, sales of gadobrine injections in public medical institutions in China have been rising year by year in recent years
Hokuriku Pharmaceutical (300016.SZ): R&D projects currently focus on high-end generic drugs, APIs and health products
Gelonghui March 15 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company's R&D projects currently focus on high-end generic drugs, APIs and health products. It involves various fields such as contrast agents, central nervous system, endocrinology, digestion, cardiovascular, etc.
Hokuriku Pharmaceutical (300016.SZ): Participating companies Shihe Gene, Zhiyou Medical, and Medicare's main businesses are involved in high-throughput gene sequencing, drug genomics, molecular diagnostic reagents for tumor targeting, brain science, and A
Gelonghui March 7 丨 Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that Hokuriku Pharmaceutical and its subsidiaries are actively exploring new models of pharmaceutical production management in the pharmaceutical field to improve operational efficiency and product quality. The main businesses of the participating companies Shihe Gene, Zhiyou Medical, and Medicare are involved in high-throughput gene sequencing, drug genomics, molecular diagnostic reagents for tumor targeting, brain science, and AI-assisted diagnosis, respectively.
Hokuriku Pharmaceutical (300016.SZ): The first and second phases of the Cangzhou branch have been officially put into operation and are running smoothly
Gelonghui, Feb. 29丨Beilu Pharmaceutical (300016.SZ) said on the investor interactive platform that the first and second phases of the Cangzhou branch have been officially put into operation and are running smoothly, and the construction of the third phase of the Cangzhou branch is progressing in an orderly manner.
Hokuriku Pharmaceutical (300016.SZ): Hypoglycemic products include glimepiride tablets and reglinide tablets
Gelonghui, Feb. 23 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company's central nervous system product, Jiuwei Zhenxin Granule, is a pure traditional Chinese medicine preparation approved by the China Food and Drug Administration to treat generalized anxiety disorder; hypoglycemic products include glimepiride tablets and reglinide tablets, which are mainly suitable for type 2 diabetes where high blood sugar cannot be effectively controlled through diet control, weight loss and exercise.
Hokuriku Pharmaceutical (300016.SZ): There are currently no plans to increase investment in the direction of brain-computer connections
Gelonghui, January 31 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company currently has no plans to increase investment in the direction of brain-computer connectivity. The participating company Shenzhen Yiwei Medical Technology Co., Ltd. is a leader in accurate diagnosis and treatment of brain diseases in China. It is a brain science digital product company that focuses on ultra-early screening and accurate diagnosis and treatment of brain diseases (stroke, Alzheimer's disease, dementia, adolescent developmental disorders, etc.). It is the only artificial intelligence enterprise in China that covers the entire process of full-brain screening and diagnosis. The company has led the industry and became the first in the country to be approved by NMPA, CE, and FDA in the fields of stroke and cognition
Hokuriku Pharmaceutical (300016.SZ) issued an advance loss and is expected to have a net loss of 50 million yuan to 75 million yuan in 2023
Hokuriku Pharmaceutical (300016.SZ) disclosed its 2023 annual results forecast, and the company is expected to belong to listed company shares...
Hokuriku Pharmaceutical (300016.SZ): A series of supplements developed around Jiuwei Zhenxin granules aims to improve sleep disorders in young and elderly people and memory problems in young people
Gelonghui, January 16 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that according to the current product plan, the series of health products developed by the company around Jiuwei Zhenxin granules aims to improve sleep disorders in young people and the elderly as well as memory problems in young people. The above products are still being reviewed, and the company will actively promote related work to obtain early approval for listing.
Hokuriku Pharmaceutical (300016.SZ): Jiuwei Zhenxin granules have begun registration in Hong Kong and Thailand, China
Gelonghui, January 11 | Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that Jiuwei Zhenxin granules are used as prescription drugs, and their sales channels are mainly hospital prescriptions, supplemented by channels such as pharmacies and e-commerce. Hokuriku Pharmaceutical has always been actively following developments in the international market and is committed to promoting the internationalization of products. Jiuwei Zhenxin Granule has begun registration work in Hong Kong, China and Thailand to create conditions for export to Southeast Asia and other places.
Hokuriku Pharmaceutical (300016.SZ): Future product pipelines will place equal emphasis on generic drugs and proprietary Chinese medicines
Gelonghui, January 5 | Hokuriku Pharmaceutical (300016.SZ) recently said during a survey receiving institutional investors that the company takes “China's top 100 pharmaceutical manufacturing enterprises” as its medium- to long-term development goal. The future product pipeline will focus on chemical generic drugs and proprietary Chinese medicines, actively expand the product pipeline around the company's key cardiovascular, digestive, neuropsychiatric, endocrine and other fields to create a rich product matrix. Proprietary Chinese medicines are the company's key focus area for the next few years. The company is focusing on building the “No. 1 anti-anxiety brand” brand series. It plans to consolidate and expand the brand influence by continuously increasing the market share of Jiuwei Zhenxin granules, and
Hokuriku Pharmaceutical (300016.SZ): Currently, planning for the fourth production site is progressing in an orderly manner
Gelonghui, January 5 | Beilu Pharmaceutical (300016.SZ) recently said during a survey receiving institutional investors that in order to advance the company's strategic layout in proprietary Chinese medicines and in conjunction with the plan to build a “fourth production base”, the company's wholly-owned subsidiary Lu Zhibao Pharmaceutical Co., Ltd. (hereinafter referred to as “Lu Zhibao”) signed a “State-owned Construction Land Use Rights Concession Contract” with the Natural Resources and Planning Bureau of Bozhou City, Anhui Province for 50 years. Bozhou in Anhui Province is the world's largest distribution center for Chinese herbal medicines, the world
Hokuriku Pharmaceutical (300016.SZ): The production workshop involved in the Cangzhou Phase III API project has been capped and has entered the production equipment installation and commissioning stage
Gelonghui, December 28, 丨 Hokuriku Pharmaceutical (300016.SZ) Investor Relations Activity Record Form stated that according to the company's latest strategic plan, the Cangzhou production base will become the company's chemical raw material production base. The “Cangzhou Phase III Raw Material Production Project” further expands the production capacity of the company's gadolinium series of raw materials, and also lays out R&D and production of raw materials for other products under development to meet growing market demand and gradually expand the market influence of the company's products. At present, the production workshop involved in the Cangzhou Phase III API project has been capped and has entered the production equipment installation and commissioning stage.
Hokuriku Pharmaceutical (300016.SZ): Comparative products obtained registration certificate from Tajikistan
Hokuriku Pharmaceutical (300016.SZ) issued an announcement. Recently, the company received approval from the Ministry of Health of Tajikistan...
Hokuriku Pharmaceutical (300016.SZ): There is some synergy with medical treatment in the fields of medical imaging, central nervous system, etc.
On December 18, Gelonghui (300016.SZ) Investor Interactive Platform stated that the company and Medicare have a certain degree of synergy in the fields of medical imaging, central nervous system, etc., and we will evaluate various opportunities for cooperation and actively discuss and experiment with the content and forms of cooperation.
Hokuriku Pharmaceutical (300016.SZ): Auction to obtain state-owned land use rights
Gelonghui, December 13|Beilu Pharmaceutical (300016.SZ) announced that its wholly-owned subsidiary Lu Zhibao Pharmaceutical Co., Ltd. recently won the right to use state-owned construction land number 2023-40 in Bozhou, Anhui Province, and signed a “State-owned Construction Land Use Right Concession Contract” with the Bozhou Municipal Bureau of Natural Resources and Planning.
Analysis
Price Target
No Data
